Search
Artiva Biotherapeutics Inc
ARTVAdd to Watchlist
9.780USD
-0.900-8.43%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
475.19MMarket Cap
LossP/E TTM
More Details of Artiva Biotherapeutics Inc Company
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Artiva Biotherapeutics Inc Info
Ticker SymbolARTV
Company nameArtiva Biotherapeutics Inc
IPO dateJul 19, 2024
CEOAslan (Fred)
Number of employees89
Security typeOrdinary Share
Fiscal year-endJul 19
Address5505 Morehouse Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18582674467
Websitehttps://www.artivabio.com/
Ticker SymbolARTV
IPO dateJul 19, 2024
CEOAslan (Fred)
Company Executives of Artiva Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
151.32K
+29.39%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-55.67%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Subhashis Banerjee, M.D.
Dr. Subhashis Banerjee, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
151.32K
+29.39%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-55.67%
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, May 11
Updated: Mon, May 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
20.28%
5AM Ventures
4.84%
VR Adviser, LLC
3.31%
VenBio Partners LLC
1.33%
Franklin Advisers, Inc.
1.07%
Other
69.16%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
20.28%
5AM Ventures
4.84%
VR Adviser, LLC
3.31%
VenBio Partners LLC
1.33%
Franklin Advisers, Inc.
1.07%
Other
69.16%
Shareholder Types
Shareholders
Proportion
Venture Capital
28.48%
Corporation
19.62%
Investment Advisor/Hedge Fund
2.00%
Private Equity
1.95%
Individual Investor
1.75%
Hedge Fund
1.21%
Investment Advisor
1.15%
Research Firm
0.14%
Pension Fund
0.04%
Other
43.64%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
123
17.01M
68.82%
-4.52M
2025Q4
113
18.19M
82.07%
+1.82K
2025Q3
113
18.19M
82.47%
-356.42K
2025Q2
106
18.54M
87.44%
-2.45M
2025Q1
93
21.00M
87.08%
-218.92K
2024Q4
86
21.21M
85.45%
+459.05K
2024Q3
67
20.75M
65.99%
+4.72M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
9.85M
39.87%
--
--
Dec 31, 2025
5AM Ventures
2.35M
9.52%
--
--
Dec 31, 2025
VR Adviser, LLC
1.61M
6.51%
--
--
Dec 31, 2025
VenBio Partners LLC
648.51K
2.62%
-500.47K
-43.56%
Dec 31, 2025
Franklin Advisers, Inc.
520.33K
2.11%
--
--
Dec 31, 2025
Revelation Capital Management, LLC
299.31K
1.21%
+299.31K
--
Dec 31, 2025
Huston (Thad Allen)
220.00K
0.89%
+220.00K
--
Mar 10, 2026
Millennium Management LLC
217.10K
0.88%
-45.06K
-17.19%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
211.62K
0.86%
-68.68K
-24.50%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
View more
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Biotechnology ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
